logo

[breadcrumb_custom]

The ABIO Stock Puzzle: Unraveling ARCA biopharma Inc’s Fluctuating Performance

ARCA biopharma Inc’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $2.16 on 04/03/24 and a low of $1.56 for the same time frame on 01/19/24.

52-week price history of ABIO Stock

A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. ARCA biopharma Inc’s current trading price is 47.22% away from its 52-week high, while its distance from the 52-week low is 103.85%. The stock’s price range during this period has spanned from $1.56 to $2.16. In the Healthcare sector, the ARCA biopharma Inc’s shares surpassed a trading volume of approximately 69.2 million for the day, which was noticeably higher compared to the average daily volume of 9.26300.0 over the past three months.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Market Capitalization and Financial Performance: An In-Depth Look

ARCA biopharma Inc (ABIO) has experienced a quarterly rise of 89.51% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 46.11M and boasts a workforce of 5 employees.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.7261, with a change in price of +1.3600. Similarly, ARCA biopharma Inc recorded 709,346 in trading volume during the last 100 days, posting a change of +73.91%.

Examining ABIO’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ABIO stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.

ABIO Stock Stochastic Average

Today, ARCA biopharma Inc’s raw stochastic average for the past 50 days stands at 70.56%, indicating a rise from the raw stochastic average of the last 20 days, which was 70.43%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 68.93% and 73.99% respectively.

ABIO Stock Price Performance Analysis

A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded an increase of 87.06%. However, over the last six months, the performance has been weaker by 58.21%. The price of ABIO increased 89.29% over the last 30 days. And in the last five days, it has surged by 85.96%.

On Key

Related Posts